Skip to content
AnalystLens

Merck Annual Report (Amendment), Year Ended Dec 31, 2023

Filing Date
Filed April 11, 2024
Period End
December 31, 2023
Security
MRK
One revenue dollarkept$0.01
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K/A filed April 11, 2024. Cited figures are marked; the original filing is the authoritative source.

This filing is an amendment (10-K/A) to Merck & Co., Inc.'s annual report for the period ending December 30, 2023, filed on April 10, 2024.

As this is a Part III and Part IV filing, it primarily incorporates by reference information from Merck's Proxy Statement for the May 28, 2024, Annual Shareholder Meeting and previously filed 10-K reports. Key information regarding directors, executive officers, corporate governance, and executive compensation is detailed within the referenced proxy statement, emphasizing adherence to a Code of Conduct and ethical business practices. Furthermore, the filing includes details on equity compensation plans, outlining the number of securities available for issuance and outstanding options as of December 31, 2023.

It also lists various exhibits, including incorporation by reference of key corporate documents, indentures, and executive compensation plans, along with the necessary certifications from the CEO and CFO. Investors should refer to the referenced Proxy Statement for comprehensive details on governance and compensation practices.

Key Highlights

  1. The filing is an amendment (10-K/A) to the 2023 annual report, primarily incorporating information by reference from the company's Proxy Statement.
  2. Details on directors, executive officers, and corporate governance are cross-referenced to the Proxy Statement for the May 28, 2024, Annual Shareholder Meeting.
  3. Executive compensation information, including various tables and potential termination/change-in-control payments, is also incorporated by reference from the Proxy Statement.
  4. Merck maintains a Code of Conduct, 'Our Values and Standards,' applicable to all employees, including senior officers, with provisions for disclosing amendments and waivers.
  5. As of December 31, 2023, there were 13,526,932 securities to be issued upon exercise of outstanding options, warrants, and rights under shareholder-approved plans.
  6. A total of 81,123,362 securities remained available for future issuance under equity compensation plans approved by security holders.
  7. The filing lists numerous exhibits, many of which are incorporated by reference from previous filings, including corporate governance documents, debt indentures, and various executive compensation and benefit plans.

Follow one dollar

Of each $1.00 of revenue in FY2023, Merck kept $0.01.

  1. Revenue$60.12B100.0%
  2. Cost of revenue−$16.13B26.8%
  3. Gross profit$43.99B73.2%
  4. Operating costs−$43.62B72.6%
  5. Operating income$365.0M0.6%
  6. Interest, other & tax$-00.0%
  7. Net income$365.0M0.6%
Computed from 10-K/AFY2023filed April 11, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2023 revenue went

$60.12B
  • R&D: $30.53B, 51% of revenue
  • Cost of revenue: $16.13B, 27% of revenue
  • SG&A: $10.50B, 17% of revenue
  • Net income: $365.0M, 0.6% of revenue
  • Other operating costs: $2.59B, 4.3% of revenue

Kept 0.6% as net incomeNet income $365.0M · 0.6%

Full revenue history →

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$60.12B$59.28B+1.4%
Cost of Revenue$16.13B$17.41B−7.4%
Gross Profit$43.99B$41.87B+5.1%
R&D Expenses$30.53B$13.55B+125.4%
SG&A Expenses$10.50B$10.04B+4.6%
Operating Income$365.00M$14.52B−97.5%
Interest Expense$1.15B$962.00M+19.1%
Net Income$365.00M$14.52B−97.5%
EPS (Basic)$0.14$5.73−97.6%
EPS (Diluted)$0.14$5.71−97.5%
Shares Outstanding (Basic)2.54B2.53B+0.2%
Shares Outstanding (Diluted)2.55B2.54B+0.2%

Frequently Asked Questions

  1. What is the primary purpose of this 10-K/A filing?

    This filing (10-K/A) is an amendment to Merck's 2023 annual report. It primarily incorporates by reference detailed information from the company's Proxy Statement for its May 28, 2024, Annual Shareholder Meeting, as well as from prior filings. It covers sections related to directors, executive officers, corporate governance, executive compensation, and exhibits.

  2. Where can I find detailed information about Merck's executive compensation and corporate governance?

    Detailed information on executive compensation, director compensation, corporate governance, executive officers, and board committees is incorporated by reference and can be found in Merck's Proxy Statement for the Annual Shareholder Meeting scheduled for May 28, 2024. Investors should consult that document for comprehensive details.

  3. What does the equity compensation plan information indicate?

    As of December 31, 2023, Merck had 13,526,932 securities available for issuance upon the exercise of outstanding options, warrants, and rights under its shareholder-approved equity compensation plans. Additionally, there were 81,123,362 securities remaining available for future issuance under these plans.

  4. Are there any new financial statements or operational updates in this filing?

    No, this specific filing (10-K/A) does not present new financial statements or detailed operational updates for the 2023 fiscal year. Instead, it directs readers to other documents, such as the previously filed 10-K and the upcoming Proxy Statement, for such information. It focuses on governance and compensation-related disclosures.